Pozen swung to a net loss of $8.1 million in the third quarter but its results exceeded Wall Street estimates.
The Chapel Hill company had revenue of $5.8 million, compared with $5.5 million during the same period a year ago. The consensus among analysts who cover the company was revenue of $5.6 million, according to Bloomberg.
Pozen had net a loss of $8.1 million, or 25 cents per share, compared with net income of $6.8 million, or 20 cents per share, during the third quarter of 2014.
Analysts had forecast a loss of 26 cents per share.
Pozen announced earlier this year that it was buying the Canadian company Tribute Pharmaceuticals and changing its name to Aralez Pharmaceuticals. The new company will reincorporate in Ireland, where the corporate tax rate is significantly lower, and trade on the Nasdaq exchange and the Toronto Stock Exchange.
The deal is expected to close in December.
Aralex is to become a specialty pharmaceutical company focused on cardiovascular treatments. The company's core product will be Yosprala, an alternative to aspirin used for treating heart disease and stroke patients. Yosprala has not yet been approved by the U.S. Food and Drug Administration.
Pozen shares were up more than 4 percent in early trading Monday. The stock is down 16 percent this year.